Corno V, Dezza M C, Lucianetti A, Codazzi D, Carrara B, Pinelli D, Parigi P C, Guizzetti M, Strazzabosco M, Melzi M L, Gaffuri G, Sonzogni V, Rossi A, Fagiuoli S, Colledan M
General Surgery III Liver and Lung Transplantation Center, Ospedali Riuniti, Bergamo, Italy.
Am J Transplant. 2007 Oct;7(10):2433-8. doi: 10.1111/j.1600-6143.2007.01945.x.
Sequential bilateral single lung-liver transplantation (SBSL-LTx) is a therapeutic option for patients with end stage lung and liver disease (ESLLD) due to cystic fibrosis (CF). A few cases have been reported, all of them were performed with the use of cardio-pulmonary by-pass (CPB). We performed SBSL-LTx in three young men affected by CF. All the recipients had respiratory failure and portal hypertension with hypersplenism. Along with lung transplants, two patients received a whole liver graft and one an extended right graft from an in situ split liver. During transplantation neither CPB nor veno-venous by-pass (VVB) were employed. Immunosuppression was based on basiliximab, tacrolimus, steroids and azathioprine. The three recipients are alive with a median follow-up of 670 days (range 244-1,533). Combined SBSL-LTx is a complex but effective procedure for the treatment of ESLLD due to CF, not necessarily requiring the use of CPB or VVB.
序贯双侧单肺-肝移植（SBSL-LTx）是治疗因囊性纤维化（CF）导致的终末期肺和肝脏疾病（ESLLD）患者的一种治疗选择。已有少数病例报道，所有这些病例均在体外循环（CPB）辅助下进行。我们对3名患有CF的年轻男性进行了SBSL-LTx。所有受者均有呼吸衰竭和门静脉高压伴脾功能亢进。除肺移植外，2例患者接受了全肝移植，1例接受了原位劈裂肝的右半肝移植。移植过程中未使用CPB或静脉-静脉转流（VVB）。免疫抑制方案基于巴利昔单抗、他克莫司、类固醇和硫唑嘌呤。3名受者均存活，中位随访时间为670天（范围244-1533天）。联合SBSL-LTx是治疗因CF导致的ESLLD的一种复杂但有效的方法，不一定需要使用CPB或VVB。
